Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan

Tomoharu Yoshizumi, Yasutsugu Takada, Ken Shirabe, Toshimi Kaido, Masaaki Hidaka, Masaki Honda, Takashi Ito, Masahiro Shinoda, Hideki Ohdan, Naoki Kawagishi, Yasuhiko Sugawara, Yasuhiro Ogura, Mureo Kasahara, Shoji Kubo, Akinobu Taketomi, Natsumi Yamashita, Shinji Uemoto, Hiroki Yamaue, Masaru Miyazaki, Tadahiro TakadaYoshihiko Maehara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The natural history of human T-cell leukemia virus type 1 (HTLV-1), which causes adult T-cell leukemia (ATL) or HTLV-1 associated myelopathy, after liver transplantation is unclear. Methods: We conducted a nationwide survey to investigate the impact of HTLV-1 status on living donor liver transplantation (LDLT) in Japan. We analyzed the cases of 82 HTLV-1-positive recipients and six HTLV-1-negative-before-LDLT recipients who received a hepatic graft from HTLV-1-positive donors. Results: Adult T-cell leukemia developed in five recipients who ultimately died. Of these five, two received grafts from HTLV-1-positive donors and three from HTLV-1-negative donors. The 1-, 3-, and 5-year ATL development rates were 4.5%, 6.5%, and 9.2%, respectively. Fulminant hepatic failure as a pre-transplant diagnosis was identified as an independent risk factor for ATL development (P = 0.001). The 1-, 3-, and 5-year survival rates for HTLV-1-positive recipients who received grafts from HTLV-1-negative donors were 79.9%, 66.1%, and 66.1%, and from HTLV-1-positive donors were 83.3%, 83.3%, and 60.8%, respectively. The 1-year survival rate for HTLV-1-negative recipients who received grafts from HTLV-1-positive donors was 33.3%. Conclusions: Fulminant hepatic failure is an independent risk factor for ATL development in HTLV-1-positive recipients. Grafts from HTLV-1-positive living donors can be transplanted into selected patients.

Original languageEnglish
Pages (from-to)333-341
Number of pages9
JournalJournal of Hepato-Biliary-Pancreatic Sciences
Volume23
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Deltaretrovirus
Living Donors
Liver Transplantation
Japan
Adult T Cell Leukemia Lymphoma
Tissue Donors
Transplants
Acute Liver Failure
Survival Rate
Spinal Cord Diseases

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Impact of human T-cell leukemia virus type 1 on living donor liver transplantation : a multi-center study in Japan. / Yoshizumi, Tomoharu; Takada, Yasutsugu; Shirabe, Ken; Kaido, Toshimi; Hidaka, Masaaki; Honda, Masaki; Ito, Takashi; Shinoda, Masahiro; Ohdan, Hideki; Kawagishi, Naoki; Sugawara, Yasuhiko; Ogura, Yasuhiro; Kasahara, Mureo; Kubo, Shoji; Taketomi, Akinobu; Yamashita, Natsumi; Uemoto, Shinji; Yamaue, Hiroki; Miyazaki, Masaru; Takada, Tadahiro; Maehara, Yoshihiko.

In: Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 23, No. 6, 01.06.2016, p. 333-341.

Research output: Contribution to journalArticle

Yoshizumi, T, Takada, Y, Shirabe, K, Kaido, T, Hidaka, M, Honda, M, Ito, T, Shinoda, M, Ohdan, H, Kawagishi, N, Sugawara, Y, Ogura, Y, Kasahara, M, Kubo, S, Taketomi, A, Yamashita, N, Uemoto, S, Yamaue, H, Miyazaki, M, Takada, T & Maehara, Y 2016, 'Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan', Journal of Hepato-Biliary-Pancreatic Sciences, vol. 23, no. 6, pp. 333-341. https://doi.org/10.1002/jhbp.345
Yoshizumi, Tomoharu ; Takada, Yasutsugu ; Shirabe, Ken ; Kaido, Toshimi ; Hidaka, Masaaki ; Honda, Masaki ; Ito, Takashi ; Shinoda, Masahiro ; Ohdan, Hideki ; Kawagishi, Naoki ; Sugawara, Yasuhiko ; Ogura, Yasuhiro ; Kasahara, Mureo ; Kubo, Shoji ; Taketomi, Akinobu ; Yamashita, Natsumi ; Uemoto, Shinji ; Yamaue, Hiroki ; Miyazaki, Masaru ; Takada, Tadahiro ; Maehara, Yoshihiko. / Impact of human T-cell leukemia virus type 1 on living donor liver transplantation : a multi-center study in Japan. In: Journal of Hepato-Biliary-Pancreatic Sciences. 2016 ; Vol. 23, No. 6. pp. 333-341.
@article{ac4a32690dd74e85a6f3aa71ed633bb1,
title = "Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan",
abstract = "Background: The natural history of human T-cell leukemia virus type 1 (HTLV-1), which causes adult T-cell leukemia (ATL) or HTLV-1 associated myelopathy, after liver transplantation is unclear. Methods: We conducted a nationwide survey to investigate the impact of HTLV-1 status on living donor liver transplantation (LDLT) in Japan. We analyzed the cases of 82 HTLV-1-positive recipients and six HTLV-1-negative-before-LDLT recipients who received a hepatic graft from HTLV-1-positive donors. Results: Adult T-cell leukemia developed in five recipients who ultimately died. Of these five, two received grafts from HTLV-1-positive donors and three from HTLV-1-negative donors. The 1-, 3-, and 5-year ATL development rates were 4.5{\%}, 6.5{\%}, and 9.2{\%}, respectively. Fulminant hepatic failure as a pre-transplant diagnosis was identified as an independent risk factor for ATL development (P = 0.001). The 1-, 3-, and 5-year survival rates for HTLV-1-positive recipients who received grafts from HTLV-1-negative donors were 79.9{\%}, 66.1{\%}, and 66.1{\%}, and from HTLV-1-positive donors were 83.3{\%}, 83.3{\%}, and 60.8{\%}, respectively. The 1-year survival rate for HTLV-1-negative recipients who received grafts from HTLV-1-positive donors was 33.3{\%}. Conclusions: Fulminant hepatic failure is an independent risk factor for ATL development in HTLV-1-positive recipients. Grafts from HTLV-1-positive living donors can be transplanted into selected patients.",
author = "Tomoharu Yoshizumi and Yasutsugu Takada and Ken Shirabe and Toshimi Kaido and Masaaki Hidaka and Masaki Honda and Takashi Ito and Masahiro Shinoda and Hideki Ohdan and Naoki Kawagishi and Yasuhiko Sugawara and Yasuhiro Ogura and Mureo Kasahara and Shoji Kubo and Akinobu Taketomi and Natsumi Yamashita and Shinji Uemoto and Hiroki Yamaue and Masaru Miyazaki and Tadahiro Takada and Yoshihiko Maehara",
year = "2016",
month = "6",
day = "1",
doi = "10.1002/jhbp.345",
language = "English",
volume = "23",
pages = "333--341",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Impact of human T-cell leukemia virus type 1 on living donor liver transplantation

T2 - a multi-center study in Japan

AU - Yoshizumi, Tomoharu

AU - Takada, Yasutsugu

AU - Shirabe, Ken

AU - Kaido, Toshimi

AU - Hidaka, Masaaki

AU - Honda, Masaki

AU - Ito, Takashi

AU - Shinoda, Masahiro

AU - Ohdan, Hideki

AU - Kawagishi, Naoki

AU - Sugawara, Yasuhiko

AU - Ogura, Yasuhiro

AU - Kasahara, Mureo

AU - Kubo, Shoji

AU - Taketomi, Akinobu

AU - Yamashita, Natsumi

AU - Uemoto, Shinji

AU - Yamaue, Hiroki

AU - Miyazaki, Masaru

AU - Takada, Tadahiro

AU - Maehara, Yoshihiko

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: The natural history of human T-cell leukemia virus type 1 (HTLV-1), which causes adult T-cell leukemia (ATL) or HTLV-1 associated myelopathy, after liver transplantation is unclear. Methods: We conducted a nationwide survey to investigate the impact of HTLV-1 status on living donor liver transplantation (LDLT) in Japan. We analyzed the cases of 82 HTLV-1-positive recipients and six HTLV-1-negative-before-LDLT recipients who received a hepatic graft from HTLV-1-positive donors. Results: Adult T-cell leukemia developed in five recipients who ultimately died. Of these five, two received grafts from HTLV-1-positive donors and three from HTLV-1-negative donors. The 1-, 3-, and 5-year ATL development rates were 4.5%, 6.5%, and 9.2%, respectively. Fulminant hepatic failure as a pre-transplant diagnosis was identified as an independent risk factor for ATL development (P = 0.001). The 1-, 3-, and 5-year survival rates for HTLV-1-positive recipients who received grafts from HTLV-1-negative donors were 79.9%, 66.1%, and 66.1%, and from HTLV-1-positive donors were 83.3%, 83.3%, and 60.8%, respectively. The 1-year survival rate for HTLV-1-negative recipients who received grafts from HTLV-1-positive donors was 33.3%. Conclusions: Fulminant hepatic failure is an independent risk factor for ATL development in HTLV-1-positive recipients. Grafts from HTLV-1-positive living donors can be transplanted into selected patients.

AB - Background: The natural history of human T-cell leukemia virus type 1 (HTLV-1), which causes adult T-cell leukemia (ATL) or HTLV-1 associated myelopathy, after liver transplantation is unclear. Methods: We conducted a nationwide survey to investigate the impact of HTLV-1 status on living donor liver transplantation (LDLT) in Japan. We analyzed the cases of 82 HTLV-1-positive recipients and six HTLV-1-negative-before-LDLT recipients who received a hepatic graft from HTLV-1-positive donors. Results: Adult T-cell leukemia developed in five recipients who ultimately died. Of these five, two received grafts from HTLV-1-positive donors and three from HTLV-1-negative donors. The 1-, 3-, and 5-year ATL development rates were 4.5%, 6.5%, and 9.2%, respectively. Fulminant hepatic failure as a pre-transplant diagnosis was identified as an independent risk factor for ATL development (P = 0.001). The 1-, 3-, and 5-year survival rates for HTLV-1-positive recipients who received grafts from HTLV-1-negative donors were 79.9%, 66.1%, and 66.1%, and from HTLV-1-positive donors were 83.3%, 83.3%, and 60.8%, respectively. The 1-year survival rate for HTLV-1-negative recipients who received grafts from HTLV-1-positive donors was 33.3%. Conclusions: Fulminant hepatic failure is an independent risk factor for ATL development in HTLV-1-positive recipients. Grafts from HTLV-1-positive living donors can be transplanted into selected patients.

UR - http://www.scopus.com/inward/record.url?scp=84975275537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975275537&partnerID=8YFLogxK

U2 - 10.1002/jhbp.345

DO - 10.1002/jhbp.345

M3 - Article

C2 - 26996829

AN - SCOPUS:84975275537

VL - 23

SP - 333

EP - 341

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 6

ER -